Unfortunately, this "tau-negative" diagnostic approach is not applicable as a biomarker for the broader spectrum of TDP-43 proteinopathy diseases, and p-tau181 is not specific for frontotemporal lobar degenerations associated with tau, which are also influenced by amyloid deposition [34]. Here, MAPT is linked to amyloidosis.